{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:27:06Z","timestamp":1787596026697,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The interplay between Antiphospholipid syndrome (APS) and migraine is very controversial; migraine is believed to be the most common neurologic symptom in APS, and there are claims that migraineurs have abnormally high Antiphospholipid antibodies (aPL), yet the reports differ widely. Nevertheless, APS could lead to various other types of headaches; both primary and secondary, leaving patients susceptible to exacerbation of symptoms, overlapping of headaches, and atypical presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim of the work<\/jats:title>\n                    <jats:p>To describe types and characteristics of headache in a cohort of patients with antiphospholipid syndrome (APS) in comparison to healthy controls. And investigate their possible relation with antiphospholipid antibodies (aPL) and MRI brain findings in patients with APS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We recruited 76 patients with APS consecutively, between February 2024 and August 2025. From Ain shams university hospital; neurology, internal medicine, and obstetric and gynecology departments, along with 60 matched controls. Patients and controls underwent neurological examination and were evaluated for headache according to the International Headache Society criteria (IHS), Impact and severity were assessed by Migraine Disability Assessment (MIDAS) and Headache Impact Test (HIT). All participants had a brain MRI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 76 patients; 70 females and 6 males, mean age for patients at presentation was 35\u2009\u00b1\u20098.73 years; mean disease duration was 5\u2009\u00b1\u20093 years; mean Body mass index (BMI) was 22.38\u2009\u00b1\u20091.46. Headache was reported by 87% of patients; of which 16 patients suffered secondary type headaches (21%); and 50 patients had primary headaches (65.7%); with migraine being the most common (35%). Anticardiolipin (ACL) antibodies were the most common aPL detected (76.4%) in APS patients. MRI brain was normal in 86% of APS patients with primary headaches, Meanwhile, APS patients with triple positive antibodies showed significantly more abnormal MRI findings (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). Headache severity was significantly more in APS patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) Factors affecting headache severity were APS disease duration, BMI, triple aPL positivity (\n                      <jats:italic>p\u2009=\u2009<\/jats:italic>\n                      0.03, 0.00, 0.02 respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Primary and secondary types of headaches are frequently reported in Patients with APS, primary headache being more common; migraine in particular. APS patients had significantly more severe headaches. MRI brain was normal in the majority of APS patients with primary headaches and healthy controls. Yet, patients with triple positive antibodies showed more abnormal MRI findings. APS disease duration, BMI, triple aPL were independent factors for headache severity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-026-02381-4","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:23:22Z","timestamp":1778477002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patterns of headache in patients with antiphospholipid syndrome in relation to autoantibodies"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1280-1764","authenticated-orcid":false,"given":"Radwa","family":"Soliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssra Gadallah","family":"Mahfouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1338-7470","authenticated-orcid":false,"given":"Rania Gamal Anwar","family":"El-Skaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warda Abdelfattah Shehata","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2381_CR1","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/ard-2023-224609","volume":"82","author":"M Barbhaiya","year":"2023","unstructured":"Barbhaiya M, Zuily S, Naden R et al (2023) ACR\/ EULAR APS Classification Criteria Collaborators. 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis 82:1258\u20131270","journal-title":"Ann Rheum Dis"},{"key":"2381_CR2","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/bjh.19635","volume":"205","author":"DJ Arachchillage","year":"2024","unstructured":"Arachchillage DJ, Platton S, Hickey K et al (2024) Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 205:855\u2013880","journal-title":"Br J Haematol"},{"issue":"4","key":"2381_CR3","first-page":"355","volume":"45","author":"R T\u0103n\u0103sescu","year":"2007","unstructured":"T\u0103n\u0103sescu R, Nicolau A, Caraiola S et al (2007) Antiphospholipid antibodies and migraine: a retrospective study of 428 patients with inflammatory connective tissue diseases. Rom J Intern Med 45(4):355\u2013363 PMID: 18767411","journal-title":"Rom J Intern Med"},{"key":"2381_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jemermed.2014.06.031","volume":"48","author":"B Johnson","year":"2014","unstructured":"Losonczy Lia, Johnson B, Sidhu J et al (2014) Seronegative Catastrophic Antiphospholipid Syndrome in a Young Female Presenting with a Headache. J Emerg Med 48:3: 294\u2013297. https:\/\/doi.org\/10.1016\/j.jemermed.2014.06.031","journal-title":"J Emerg Med"},{"key":"2381_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/0885066606287041","volume":"21","author":"SK Vora","year":"2006","unstructured":"Vora SK (2006) Catastrophic antiphospholipid syndrome. J Intensive Care Med 21:144\u2013159","journal-title":"J Intensive Care Med"},{"key":"2381_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1191\/096120301678646119","volume":"10","author":"MJ Cuadrado","year":"2001","unstructured":"Cuadrado MJ, Khamashta MA, Hughes GRV (2001) Sticky blood and headache. Lupus 10:392\u2013393","journal-title":"Lupus"},{"key":"2381_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/pmj.79.928.81","volume":"79","author":"GRV Hughes","year":"2003","unstructured":"Hughes GRV (2003) Migraine, memory loss, and _multiple sclerosis. Neurological features of the antiphospholipid (Hughes) syndrome. Postgrad Med 79:81\u201383","journal-title":"Postgrad Med"},{"key":"2381_CR8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1177\/0961203309106832","volume":"18","author":"R Cervera","year":"2009","unstructured":"Cervera R, Boffa M-C, Khamashta MA, Hughes GRV (2009) The Euro- Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 18:889\u2013893","journal-title":"Lupus"},{"key":"2381_CR9","doi-asserted-by":"publisher","unstructured":"Islam MA, Alam F, Kah Keng Wong (2017) Comorbid association of antiphospholipid antibodies and migraine: A systematic review and meta analysis. Autoimmun Rev 512\u2013522. https:\/\/doi.org\/10.1016\/j.autrev.2017.03.005","DOI":"10.1016\/j.autrev.2017.03.005"},{"key":"2381_CR10","first-page":"245","volume":"11","author":"P Bruno","year":"2007","unstructured":"Bruno P, Carpino F, Carpino G, Zicari A (2007) An overview on immune system and migraine. Eur Rev Med Pharmacol Sci 11:245\u2013248","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2381_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/BF02527632","volume":"7","author":"C Heesen","year":"1993","unstructured":"Heesen C, Engler F (1993) Immunological abnormalities in migraine and cluster headache epiphenomenon or pathogenetic factors? Schmerz 7:8\u201314","journal-title":"Schmerz"},{"key":"2381_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1046\/j.1468-2982.2001.00196.x","volume":"21","author":"R Kemper","year":"2001","unstructured":"Kemper R, Meijler W, Korf J, Ter Horst G (2001) Migraine and function of the immune system: a meta-analysis of clinical literature published between 1966 and 1999. Cephalalgia 21:549\u2013557","journal-title":"Cephalalgia"},{"issue":"1","key":"2381_CR13","first-page":"3","volume":"4","author":"R Akintayo","year":"2016","unstructured":"Akintayo R, Aworinde O, Olawumi H, Yusuf I (2016) Antiphospholipid syndrome in Africa: a review. Afr J Rheumatol 4(1):3\u20138","journal-title":"Afr J Rheumatol"},{"key":"2381_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295\u2013306","journal-title":"J Thromb Haemost"},{"key":"2381_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders. Cephalalgia 33:629\u2013808","journal-title":"Cephalalgia"},{"issue":"1","key":"2381_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.11607\/ofph.2102","volume":"33","author":"D Mourad","year":"2019","unstructured":"Mourad D, Hajj A, Hallit S, Ghossoub M, Khabbaz LR (2019) Validation of the Arabic version of the migraine disability assessment scale among Lebanese patients with migraine. J Oral Facial Pain Headache 33(1):47\u201353","journal-title":"J Oral Facial Pain Headache"},{"issue":"5","key":"2381_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/head.14719","volume":"64","author":"M Hussein","year":"2024","unstructured":"Hussein M, Hassan A, Nada MAF et al (2024) Reliability, validity, and responsiveness of the Arabic version of HIT-6 questionnaire in patients with migraine indicated for preventive therapy: A multi-center study. Headache 64(5):500\u2013508. https:\/\/doi.org\/10.1111\/head.14719. Epub 2024 Apr 23. PMID: 38651363","journal-title":"Headache"},{"key":"2381_CR18","first-page":"453","volume":"1","author":"S Rudwan","year":"2003","unstructured":"Rudwan S (2003) Beck Depression Inventory (BDI). J King Saud Univ Sci 1:453\u2013486","journal-title":"J King Saud Univ Sci"},{"key":"2381_CR19","first-page":"521","volume":"65","author":"D Gladman","year":"2002","unstructured":"Gladman D, Iban ez D, Urowitz M (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 65:521\u2013530","journal-title":"J Rheumatol"},{"issue":"2","key":"2381_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.crad.2012.06.110","volume":"68","author":"YP Goh","year":"2013","unstructured":"Goh YP, Naidoo P, Ngian GS (2013) Imaging systemic lupus erythematosus. Part I: CNS, cardiovascular, and thoracic manifestations. Clin Radiol 68(2):181\u2013191. https:\/\/doi.org\/10.1016\/j.crad.2012.06.110","journal-title":"Clin Radiol"},{"key":"2381_CR21","doi-asserted-by":"crossref","unstructured":"Bashir A, Lipton RB, Ashina S, Ashina M (2013) Migraine and structural changes in the brain: a systematic review and meta-analysis. Neurology 1260\u20131268","DOI":"10.1212\/WNL.0b013e3182a6cb32"},{"key":"2381_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.autrev.2014.05.001","volume":"13","author":"ML Bertolaccini","year":"2014","unstructured":"Bertolaccini ML, Amengual O, Andreoli L et al (2014) 14th international congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13:917\u2013930","journal-title":"Autoimmun Rev"},{"key":"2381_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-016-0568-x","volume":"18","author":"CM Yelnik","year":"2016","unstructured":"Yelnik CM, Kozora E, Appenzeller S (2016) Non-stroke central neurologic manifestations in antiphospholipid syndrome. Curr Rheumatol Rep 18:1\u20139","journal-title":"Curr Rheumatol Rep"},{"key":"2381_CR24","doi-asserted-by":"publisher","first-page":"106664","DOI":"10.1016\/j.msard.2025.106664","volume":"103","author":"P Gklinos","year":"2025","unstructured":"Gklinos P, Evangelopoulos \u039cE, Velonakis G et al (2025) Migraine and tension-type headache in multiple sclerosis: A two-year, prospective, longitudinal, controlled study. Multiple Scler Relat Disorders 103:106664. https:\/\/doi.org\/10.1016\/j.msard.2025.106664","journal-title":"Multiple Scler Relat Disorders"},{"key":"2381_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/978-3-319-24535-5_9","volume-title":"Connective Tissue Disease","author":"K Schreiber","year":"2016","unstructured":"Schreiber K, Jacobsen S (2016) Neuropsychiatric systemic lupus erythematosus. In: Roccatello D, Emmi L (eds) Connective Tissue Disease, 1st edn. Springer International Publishing, Switzerland, pp 113\u2013131","edition":"1"},{"key":"2381_CR26","unstructured":"Noureldine MH, Haydar A, Berjawi A et al (2016) The evidence around migraine headaches in antiphospholipid syndrome and antiphospholipid antibody-positive patients. 15th International Congress on Antiphospholipid Antibodies. 25:84\u201384PP126"},{"key":"2381_CR27","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/art.10187","volume":"46","author":"R Cervera","year":"2002","unstructured":"Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019\u20131027","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2381_CR28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/0961203307077108","volume":"16","author":"M Garc\u0131\u00b4a-Carrasco","year":"2007","unstructured":"Garc\u0131\u00b4a-Carrasco M, Galarza C, Go\u00b4 mez-Ponce M et al (2007) Antiphospholipid syndrome in Latin American patients: Clinical and immunologic characteristics and comparison with European patients. Lupus 16(5):366\u2013373 Doi: 10.1177\/0961203307077108. PMID: 17576741","journal-title":"Lupus"},{"key":"2381_CR29","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/j.1538-7836.2011.04348.x","volume":"9","author":"C Cavestro","year":"2011","unstructured":"Cavestro C, Micca G, Molinari F et al (2011) Migraineurs show a high prevalence of antiphospholipid antibodies. J Thromb Haemost 9:1350\u20131354","journal-title":"J Thromb Haemost"},{"key":"2381_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/1118-8561.145734","volume":"12","author":"Y Nyandaiti","year":"2009","unstructured":"Nyandaiti Y, Bwala S, Gadzama A et al (2009) Antiphospholipids antibodies and migraine. Sahel Med J 12:42\u201345","journal-title":"Sahel Med J"},{"key":"2381_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/pgmj.70.819.37","volume":"70","author":"CG Suresh","year":"1994","unstructured":"Suresh CG, Neal D, Coupe MO (1994) \u2013 Warfarin treatment and migraine. Postgrad Med J 70:37","journal-title":"Postgrad Med J"},{"key":"2381_CR32","doi-asserted-by":"publisher","unstructured":"Badry R, Gamal RM (2015) Different types of headaches in patients with systemic lupus erythematosus. Int J Neurosci 125(5):357\u201360. https:\/\/doi.org\/10.3109\/00207454.2014.951041. Epub 2014 Sep 3. PMID: 25185021","DOI":"10.3109\/00207454.2014.951041"},{"key":"2381_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s43166-021-00078-x","volume":"48","author":"G Elolemy","year":"2021","unstructured":"Elolemy G, Al Rashidi A, Youssry D et al (2021) Headache in patients with systemic lupus erythematosus: characteristics, brain MRI patterns, and impact. Egypt Rheumatol Rehabil 48:31. https:\/\/doi.org\/10.1186\/s43166-021-00078-x","journal-title":"Egypt Rheumatol Rehabil"},{"key":"2381_CR34","doi-asserted-by":"crossref","unstructured":"Hagen NA, Stevens JC, Michet CJ (1990) Trigeminal sensory neuropathy associated with connective tissue diseases. Neurology 40(6):891","DOI":"10.1212\/WNL.40.6.891"},{"issue":"3","key":"2381_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.31138\/mjr.33.3.333","volume":"33","author":"D Maikap","year":"2022","unstructured":"Maikap D, Padhan P (2022) Trigeminal Neuralgia as an Initial Presentation of Systemic Autoimmune Diseases: A Case Series. Mediterr J Rheumatol 33(3):333\u2013338. https:\/\/doi.org\/10.31138\/mjr.33.3.333. PMID: 36531419; PMCID: PMC9727472","journal-title":"Mediterr J Rheumatol"},{"key":"2381_CR36","doi-asserted-by":"publisher","unstructured":"VanderPluym J, Richer L (2015) Tic versus TAC: differentiating the neuralgias (trigeminal neuralgia) from the cephalalgias (SUNCT and SUNA). Curr Pain Headache Rep 19(2):473. https:\/\/doi.org\/10.1007\/s11916-014-0473-9. PMID: 25501956","DOI":"10.1007\/s11916-014-0473-9"},{"key":"2381_CR37","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1212\/WNL.50.5.1433","volume":"50","author":"G Tietjen","year":"1998","unstructured":"Tietjen G, Day M, Norris L et al (1998) Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: A prospective study. Neurology 50:1433\u20131440","journal-title":"Neurology"},{"key":"2381_CR38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000108693","volume":"3","author":"P Hinse","year":"1993","unstructured":"Hinse P, Schulz A, Haag F et al (1993) Anticardiolipin antibodies in oculocerebral ischemia and migraine: prevalence and prognostic value. Cerebrovasc Dis 3:168\u2013173","journal-title":"Cerebrovasc Dis"},{"key":"2381_CR39","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/j.1468-2982.2008.01646.x","volume":"28","author":"F Williams","year":"2008","unstructured":"Williams F, Cherkas L, Bertolaccini M et al (2008) Migraine and antiphospholipid antibodies: No association found in migraine-discordant monozygotic twins. Cephalalgia 28:1048\u20131052","journal-title":"Cephalalgia"},{"key":"2381_CR40","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/j.1538-7836.2011.04348.x","volume":"9","author":"C Cavestro","year":"2011","unstructured":"Cavestro C, Micca G, Molinari F, Bazzan M et al (2011) Migraineurs show a high prevalence of antiphospholipid antibodies. J Thromb Haemost 9:1350\u20131354","journal-title":"J Thromb Haemost"},{"key":"2381_CR41","first-page":"176","volume":"254","author":"C Burcin","year":"2007","unstructured":"Burcin C, Cojocaru IM, CojocaruM, Atanasiu A (2007) Prevalence of anticardiolipin antibodies, lupus anticoagulant, and antibeta 2-glycoprotein I antibodies in migraine with aura. J Neurol 254:176","journal-title":"J Neurol"},{"key":"2381_CR42","doi-asserted-by":"publisher","unstructured":"Adel M, Ali EA, Hafez, Shafica I, Ibrahim et al (2025) Clinical, immunological features and relation to clinical phenotypes in patients with antiphospholipid syndrome. Egypt Rheumatologist 99\u2013103. https:\/\/doi.org\/10.1016\/j.ejr.2025.03.001","DOI":"10.1016\/j.ejr.2025.03.001"},{"key":"2381_CR43","doi-asserted-by":"publisher","unstructured":"Lazzaroni MG, Fredi M, Andreoli L et al (2019) Triple antiphospholipid (aPL) antibodies positivity is associated with pregnancy complications in aPL carriers: a multicenter study on 62 pregnancies. Front Immunol 10:1948. https:\/\/doi.org\/10.3389\/fimmu.2019.01948. PMID: 31475009; PMCID: PMC6702797","DOI":"10.3389\/fimmu.2019.01948"},{"key":"2381_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jocn.2023.07.007","volume":"115","author":"M Tiam","year":"2023","unstructured":"Tiam M, Saffari K, Kavanagh B, Ormseth et al (2023) Severe obesity is associated with increased migraine severity and frequency: A retrospective cohort study. J Clin Neurosci Volume 115:8\u201313. https:\/\/doi.org\/10.1016\/j.jocn.2023.07.007","journal-title":"J Clin Neurosci Volume"},{"issue":"4","key":"2381_CR45","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1212\/01.wnl.0000197218.05284.82","volume":"66","author":"ME Bigal","year":"2006","unstructured":"Bigal ME, Liberman JN, Lipton RB (2006) Obesity and migraine: a population study. Neurology 66(4):545\u2013550","journal-title":"Neurology"},{"issue":"4","key":"2381_CR46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11916-005-0039-y","volume":"9","author":"A Porter","year":"2005","unstructured":"Porter A, Gladstone J, Dodick D (2005) Migraine and White Matter Hyperintensities. Curr Pain Headache Rep 9(4):289\u2013293. https:\/\/doi.org\/10.1007\/s11916-005-0039-y- Pubmed","journal-title":"Curr Pain Headache Rep"},{"issue":"11","key":"2381_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0045-1812886","volume":"83","author":"V Viuniski","year":"2025","unstructured":"Viuniski V, Ruffini M, Souza A et al (2025) Unraveling the Relationship Between White Matter Lesions in MRI and Migraine: A Systematic Review. Arq Neuropsiquiatr 83(11):1\u201313. https:\/\/doi.org\/10.1055\/s-0045-1812886- Pubmed","journal-title":"Arq Neuropsiquiatr"},{"key":"2381_CR48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1468-2982.2009.01904.x","volume":"30","author":"MC Kruit","year":"2010","unstructured":"Kruit MC, van Buchem MA, Launer LJ et al (2010) Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA Study. Cephalalgia 30:129\u2013136","journal-title":"Cephalalgia"},{"issue":"01","key":"2381_CR49","doi-asserted-by":"publisher","first-page":"10881","DOI":"10.1038\/s41598-021-90341-0","volume":"11","author":"LA Dobrynina","year":"2021","unstructured":"Dobrynina LA, Suslina AD, Gubanova MV et al (2021) White matter hyperintensity in different migraine subtypes. Sci Rep 11(01):10881. https:\/\/doi.org\/10.1038\/s41598-021-90341-0","journal-title":"Sci Rep"},{"key":"2381_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41983-021-00430-0","volume":"58","author":"EM Fahmy","year":"2022","unstructured":"Fahmy EM, Hamdy MSE, Mahmoud RM et al (2022) Association between blood coagulability and migraine. Egypt J Neurol Psychiatry Neurosurg 58:1. https:\/\/doi.org\/10.1186\/s41983-021-00430-0","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"issue":"3","key":"2381_CR51","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/0333102417694881","volume":"38","author":"MA Islam","year":"2018","unstructured":"Islam MA, Alam F, Gan SH et al (2018) Coexistence of antiphospholipid antibodies and cephalalgia. Cephalalgia 38(3):568\u2013580 doi: 10.1177\/0333102417694881. Epub 2017 Feb 20. PMID: 28952322","journal-title":"Cephalalgia"},{"key":"2381_CR52","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/head.14917","volume":"65","author":"F De Santis","year":"2025","unstructured":"De Santis F, Foschi M, Romoli M et al (2025) Do antithrombotic drugs have a role in migraine prevention? A systematic review. Headache 65:709\u2013727. https:\/\/doi.org\/10.1111\/head.14917","journal-title":"Headache"},{"issue":"1","key":"2381_CR53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-025-01987-4","volume":"26","author":"R Soliman","year":"2025","unstructured":"Soliman R, Fahmy N, Swelam MS (2025) Headache types and characteristics in patients with Amyotrophic Lateral Sclerosis. J Headache Pain 26(1):53. https:\/\/doi.org\/10.1186\/s10194-025-01987-4. PMID: 40075315; PMCID: PMC11900350","journal-title":"J Headache Pain"},{"issue":"10","key":"2381_CR54","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/j.1525-1497.2004.3002.x","volume":"19","author":"J Elston Lafata","year":"2004","unstructured":"Elston Lafata J, Moon C, Leotta C et al (2004) The medical care utilization and costs associated with migraine headache. J Gen Intern Med 19(10):1005\u20131012. https:\/\/doi.org\/10.1111\/j.1525-1497.2004.3002.x","journal-title":"J Gen Intern Med"},{"key":"2381_CR55","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s10194-025-02163-4","volume":"26","author":"M Agbetou","year":"2025","unstructured":"Agbetou M, Avolonto T, Houehanou C et al (2025) Direct cost of headache treatment in Benin, a West African country, in 2023. J Headache Pain 26:201. https:\/\/doi.org\/10.1186\/s10194-025-02163-4","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02381-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02381-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02381-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:15:24Z","timestamp":1779268524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02381-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2381"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02381-4","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was approved by the ethical committee and institutional review board of the faculty of medicine, Ain Shams University, Cairo, Egypt with the number FMASU R150\/2025, in accordance with the Declaration of Helsinki (WMA, 1964). All participants signed informed written consent for participation and publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}